Informatie:
Fout:
ID
16131
Beschrijving
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02338921
Link
https://clinicaltrials.gov/show/NCT02338921
Trefwoorden
Versies (2)
- 30-06-16 30-06-16 -
- 01-07-16 01-07-16 - Julian Varghese
Geüploaded op
1 juli 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Type 2 Diabetes NCT02338921
Eligibility Type 2 Diabetes NCT02338921
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT02338921
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Age
Item
20 ≤ age < 80 years
boolean
C0001779 (UMLS CUI [1])
hba1c
Item
hba1c ≥ 7 %
boolean
C0019018 (UMLS CUI [1])
Combination Therapy glimepiride Metformin
Item
combination therapy with glimepiride and metformin over 2 months.
boolean
C0061323 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0025598 (UMLS CUI [2])
glimepiride Dosage mg/day
Item
dosage of glimepiride : 1-8mg/day
boolean
C0061323 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
Metformin Dosage mg/day
Item
dosage of metformin : 500-2550mg/day
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
Diabetes Mellitus, Insulin-Dependent | Gestational Diabetes | Secondary diabetes mellitus
Item
type 1 diabetes, gestational diabetes, or secondary forms of diabetes
boolean
C0011854 (UMLS CUI [1])
C0085207 (UMLS CUI [2])
C0271640 (UMLS CUI [3])
C0085207 (UMLS CUI [2])
C0271640 (UMLS CUI [3])
Medical contraindication sitagliptin | Medical contraindication dapagliflozin | Medical contraindication lobeglitazone
Item
contraindication to sitagliptin or dapagliflozin or lobeglitazone
boolean
C1301624 (UMLS CUI [1,1])
C1565750 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C2353951 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C2744790 (UMLS CUI [3,2])
C1565750 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C2353951 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C2744790 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
pregnant or breast feeding women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Pharmaceutical Preparations Affecting Glycaemia control | Steroids
Item
medication which affect glycemic control (ex. steroid)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C3267174 (UMLS CUI [1,3])
C0038317 (UMLS CUI [2])
C0392760 (UMLS CUI [1,2])
C3267174 (UMLS CUI [1,3])
C0038317 (UMLS CUI [2])
Disease Affecting drug efficacy | Disease Affecting drug safety
Item
disease which affect efficacy and safety of drugs
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0598333 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0678800 (UMLS CUI [2,3])
C0392760 (UMLS CUI [1,2])
C0598333 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0678800 (UMLS CUI [2,3])
Illness Major | Liver diseases | Kidney Failure | Heart Diseases | Malignant Neoplasms
Item
any major illness (liver disease, renal failure, heart disease, cancer, etc)
boolean
C0221423 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2])
C0035078 (UMLS CUI [3])
C0018799 (UMLS CUI [4])
C0006826 (UMLS CUI [5])
C0205164 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2])
C0035078 (UMLS CUI [3])
C0018799 (UMLS CUI [4])
C0006826 (UMLS CUI [5])
contraindication Antidiabetics Oral
Item
not appropriate for oral antidiabetic agent
boolean
C3146298 (UMLS CUI [1,1])
C0935929 (UMLS CUI [1,2])
C1527415 (UMLS CUI [1,3])
C0935929 (UMLS CUI [1,2])
C1527415 (UMLS CUI [1,3])